INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 202 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q2 2020. The put-call ratio across all filers is 1.14 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2020 | $688,000 | +72.9% | 16,600 | +100.0% | 0.23% | -4.6% |
| Q2 2020 | $398,000 | -23.9% | 8,300 | 0.0% | 0.24% | -48.1% |
| Q1 2020 | $523,000 | -49.2% | 8,300 | 0.0% | 0.46% | -38.0% |
| Q4 2019 | $1,029,000 | +86.8% | 8,300 | 0.0% | 0.75% | +103.8% |
| Q3 2019 | $551,000 | -16.5% | 8,300 | 0.0% | 0.37% | -8.5% |
| Q2 2019 | $660,000 | -28.9% | 8,300 | 0.0% | 0.40% | -31.0% |
| Q1 2019 | $928,000 | +114.3% | 8,300 | +93.0% | 0.58% | +41.7% |
| Q4 2018 | $433,000 | -20.3% | 4,300 | 0.0% | 0.41% | +17.1% |
| Q3 2018 | $543,000 | +50.4% | 4,300 | 0.0% | 0.35% | +42.9% |
| Q2 2018 | $361,000 | +36.2% | 4,300 | 0.0% | 0.24% | +40.0% |
| Q1 2018 | $265,000 | +5.6% | 4,300 | 0.0% | 0.18% | +19.0% |
| Q4 2017 | $251,000 | +0.4% | 4,300 | 0.0% | 0.15% | +14.0% |
| Q3 2017 | $250,000 | +16.8% | 4,300 | +230.8% | 0.13% | +3.2% |
| Q3 2016 | $214,000 | +15.7% | 1,300 | 0.0% | 0.12% | -6.7% |
| Q2 2016 | $185,000 | +10.8% | 1,300 | 0.0% | 0.13% | +12.6% |
| Q1 2016 | $167,000 | – | 1,300 | – | 0.12% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 640,688 | $9,514,000 | 1.49% |
| CM Management, LLC | 45,000 | $668,000 | 0.50% |
| EULAV Asset Management | 660,000 | $9,801,000 | 0.26% |
| DLD Asset Management, LP | 225,200 | $3,346,000 | 0.24% |
| Virtus ETF Advisers LLC | 21,387 | $318,000 | 0.14% |
| GSA CAPITAL PARTNERS LLP | 79,145 | $1,175,000 | 0.12% |
| Hennion & Walsh Asset Management, Inc. | 136,720 | $2,030,000 | 0.11% |
| ALTRINSIC GLOBAL ADVISORS LLC | 168,800 | $2,507,000 | 0.08% |
| Inspire Investing, LLC | 31,868 | $473,000 | 0.06% |
| DUALITY ADVISERS, LP | 51,196 | $760,000 | 0.06% |